| 000 | 01789 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518062501.0 | ||
| 264 | 0 | _c20200420 | |
| 008 | 202004s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/annrheumdis-2019-215386 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMease, Philip J | |
| 245 | 0 | 0 |
_aA head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _c01 2020 |
||
| 300 |
_a123-131 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdalimumab _xtherapeutic use |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Psoriatic _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aSingle-Blind Method |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSmolen, Josef S | |
| 700 | 1 | _aBehrens, Frank | |
| 700 | 1 | _aNash, Peter | |
| 700 | 1 | _aLiu Leage, Soyi | |
| 700 | 1 | _aLi, Lingnan | |
| 700 | 1 | _aTahir, Hasan | |
| 700 | 1 | _aGooderham, Melinda | |
| 700 | 1 | _aKrishnan, Eswar | |
| 700 | 1 | _aLiu-Seifert, Hong | |
| 700 | 1 | _aEmery, Paul | |
| 700 | 1 | _aPillai, Sreekumar G | |
| 700 | 1 | _aHelliwell, Philip S | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 79 _gno. 1 _gp. 123-131 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/annrheumdis-2019-215386 _zAvailable from publisher's website |
| 999 |
_c30154038 _d30154038 |
||